A brand new 2026 survey confirms what oncologists have been quietly worried about. And in India, the gap is even wider.
One week ago, a survey result landed in the medical press that every oncologist in India should see.
The 2026 Prevent Cancer Foundation Early Detection Survey found that only 37% of Gen Z adults had any routine medical appointment or cancer screening in the last year- the lowest proportion of any generation surveyed. And nearly half don’t even know whether cancer screenings exist for their age group.
This is a US survey. But the pattern it describes is, if anything, worse in India.
India’s Double Problem
In India, young adults face a version of this problem with an extra layer of complexity.
Over 70% of cancer cases in India are diagnosed at advanced stages. Only 29% of cancers are caught early – and for breast and lung cancer, only 15% are identified at stages I or II.
India is also classified as having no formal national screening programme for breast or colorectal cancer as of 2026 – placed in the ‘No programme’ category for both in the WHO’s CanScreen5 mapping. The infrastructure simply doesn’t exist at scale to catch young people before their cancer advances.
The result is a generation of young Indian adults growing up in a country where:
- Cancer is rising
- Screening infrastructure is limited
- Awareness is low
- And the cultural instinct is still to seek care only when symptoms become undeniable
Why This Matters Specifically for Young People
When cancer is caught at an advanced stage in a 65-year-old, the tragedy is profound. When it is caught at an advanced stage in a 30-year-old, the tragedy is compounded by decades of life affected. A 30 yr. old is the working one, the hope of the family, the support pillar of the elders.
Young adults with cancer also face a specific biological challenge – their cancers are often more genomically complex, more aggressive, and less well-characterised by the research that was designed around older patient populations. A 28-year-old with colorectal cancer may carry a very different set of molecular drivers than a 65-year-old with the same diagnosis. Treating them identically, without molecular profiling is clinically inadequate.
The Tools That Can Close the Gap
Enough of the disheartening statistics. The encouraging reality is that precision oncology has the tools to address this, and for young people specifically, these tools are especially valuable:
- Hereditary cancer panel testing – for young adults with family histories of breast, ovarian, colorectal, or pancreatic cancer, comprehensive hereditary cancer panel testing identifies genetic risk before cancer develops. This is the earliest possible intervention point.
- Liquid biopsy – for young adults already diagnosed, a liquid biopsy test provides a real-time molecular snapshot of tumour biology from a simple blood draw, enabling treatment decisions that tissue alone cannot support, and monitoring disease without repeat invasive procedures.
- Minimal residual disease(MRD) testing – for young cancer survivors who have decades of life ahead, MRD testing catches molecular evidence of recurrence months before imaging, giving them the widest possible window to act.
At 1Cell.Ai, our platform spans all three of these needs; from OncoRisk for genetic risk assessment, to OncoIndx® for comprehensive genomic profiling, to OncoMonitor® and MIRAGE for post-treatment MRD monitoring. Because for a 30-year-old cancer patient in India, the standard “watch and wait” approach is not good enough.
The 37% problem is real. The tools to address it exist. The only thing missing is the conversations and we are here to start it.
